Charles River Laboratories International, Inc.
NYSECharles River Laboratories heads into mid-June with an interesting split: a high-profile analyst upgrade landed this morning, even as short sellers have been steadily rebuilding positions over the past two weeks. The analyst story is the clearest catalyst of the week. Morgan Stanley's Ricky Goldwasser upgraded CRL to Overweight from Equal-Weight this morning — a move that matters…
CRL short interest fell 22.9% over the past week to 6.95% of float, driven by covering activity as stock stabilized around $169. Cost to borrow eased to 0.43%, down 14% week-over-week, signaling reduced hedging pressure. Utilization sits at just 11%, near a 52-week low, indicating ample shares available for borrowing despite the recent short squeeze unwind.
Snapshot as of 30 Jun 2026
Charles River Laboratories heads into mid-June with an interesting split: a high-profile analyst upgrade landed this morning, even as short sellers have been steadily rebuilding positions over the past two weeks. The…
Charles River Laboratories drops into its May 6 earnings call with a mixed but charged setup: short interest has climbed sharply over the past month, the stock is down nearly 9% on the week, and yet options traders…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CRL — free to start on ORTEX.
Sign up for free →Open CRL on ORTEX